108 results about "Renal damage" patented technology

The present invention relates to methods of detecting renal transplant rejection and other forms of renal damage. Protein markers or renal damage are provided, along with assays for detecting said markers. Also provided are methods for identifying markers of renal damage.

The invention provides a test paper for semi-quantitatively detecting colloid selenium in microdose albumin in urine. The test paper can be applied in the fields of early diagnosis of diabetic nephropathy, hypertensive nephropathy and preeclampsia and injury of kidney caused by various poisonous substances. A plastic bottom plate of the test paper is orderly glued with a sampling liquid absorption part, a colloid selenium labeling part, a detection reaction part and a water absorption part, wherein the colloid selenium labeling part is a single-cloning antibody 1 which is coated by a glass fiber membrane, or acetic acid fiber membrane, or nylon membrane and labeled by the colloid selenium; the detection reaction part is a nitrocellulose membrane which is provided with two detection bands and quality control bands, T1 is a single-cloning antibody 2 which is precisely quantitative, and T2 is the single-cloning antibody 2 with a certain concentration; and the quality control bands are coated by antiplague IgG. The invention provides a method for semi-quantitatively detecting the microdose albumin in a urine sample conveniently, visually and quickly.

It is intended to provide a safe and highly stable peritoneal dialysate which causes neither peritoneal membrane disorders nor peritoneal sclerosis in frequently repeated peritoneal dialysis treatment, can protect the residual renal functions in chronic renal failure and inhibit the progress of renal damage over a long period of time, and enables peritoneal dialysis treatment in a diabetic patient. A peritoneal dialysate which contains 0.05 to 3.5 w/v% of taurine and 0.1 to 6.5 w/v% of trehalose as osmotic agents and having a pH value regulated to 6.5 to 7.5.

The invention discloses a building method of an acute hyperuricemia renal damage mouse model. The method comprises the following steps of experiment mice are subjected to molding experiment for many days by using xanthine, ethambutol and oteracil potassium as molding agents; obtaining the acute hyperuricemia renal damage mouse model; observing the body weight, the serum uric acid level and the renal function change of the experiment mice and the kidney pathological change; the renal damage effect of the molding agent on the experiment mice is analyzed. The mice are used as model animals; the serum uric acid level of the mice is equivalent to the uric acid level of a hyperuricemia patient; the serum uric acid level is stable and can easily reappear; meanwhile, the combined effect of uric acid precursors of hypoxanthine is used; the uric acid excreted substances of ethambutol and uricase inhibitors of oteracil potassium are reduced; the acute hyperuricemia renal damage mouse model is built; the molding time is short; the model conforms to the clinical characteristics of human body hyperuricemia renal damage, and is applicable to screening hyperuricemia renal damage resisting medicine.

The present invention is directed to a pet food and its use in reducing renal damage in companion animals. More particularly, the pet food maintains muscle mass in animals with renal conditions or animals at risk for developing a renal condition.

A protein [kidney regeneration factor (KRGF-1)] whose expression is increased at the time of regeneration of damaged tissues in patients with renal diseases is isolated, and a DNA encoding the protein and an antibody recognizing the protein are produced. These materials can be utilized in screening of therapeutic agents for regenerating damaged renal tissues and in diagnosis of renal damage.

The invention discloses a constructing method for a subacute hyperuricemia renal damage mouse model. The method comprises the following steps that yeast cream and oteracil potassium are taken as a molding agent, a molding experiment is constantly carried out on an experiment mouse for multiple days, a subacute hyperuricemia renal damage mouse model is acquired, wherein during the molding experiment process, the yeast cream is given to the experiment mouse every day, and after the yeast cream is given to the experiment mouse in the last day of the molding experiment, the oteracil potassium is given to the experiment mouse; the weight, serum uric acid level, renal function change and renal pathology change of the experiment mouse are observed, and damage of the molding agent to the experiment mouse is analyzed. According to the constructing method, the mouse is taken as a model animal, the yeast cream in which a uric acid precusor substance is added for a long term is adopted, the oteracil potassium as a uricase inhibitor is taken as the molding agent and is used, and the subacute hyperuricemia renal damage mouse model with stable effect is in accordance with clinical features and issuccessfully constructed.

The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted oligosaccharide, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the oligosaccharide is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.

The invention relates to a method for determining the presence of renal damage in an individual and also to a method for detecting one or several proteins selected from the list comprising Reg3B, fetuin B, Ras-related GTP-binding protein A serine protease inhibitor A3L, subunit 1 of COP9, gamma subunit of ATP synthase, gelsolin, ribonuclease UK114, aminoacylase 1A, alpha-enolase, keratin 5, parvalbumin alpha, ribonuclease 4 or serine protease inhibitor A3K. The renal damage may be acute renal failure. Said renal pathologies may be caused by the administration of a nephrotoxic agent, wherein the nephrotoxic agent may be an aminoglycoside antibiotic such as gentamicin, or cisplatin. The invention also provides means to differentiate the renal damage or renal failure induced by gentamicin from that induced by cisplatin, through the biochemical analysis of the urinary level of Reg3B and/or gelsolin, or fragments thereof.

The invention discloses a gliquidone compound preparation capable of reducing renal damage. The gliquidone compound preparation capable of reducing renal damage is prepared from main drugs and auxiliary materials, and is characterized in that the main drugs are prepared from 20-30% (w/w) of gliquidone, 15-25% (w/w) of ligustrazine and the balance of radix notoginseng extract, wherein the dosage of the radix notoginseng extract is counted based on the mass of dry powder; the radix notoginseng extract is extracted from radix notoginseng, and comprises four types of substances, namely saponin, flavone, amino acid and polyose. The gliquidone compound preparation is supplemented with the radix notoginseng extract and the ligustrazine, so that the gliquidone dosage is reduced, and further the influence of the gliquidone on the renal function of a patient is reduced; the three types of drugs achieve a synergetic effect, so that the blood glucose is reduced, functions of glomeruli are protected, the glomerular filtration capability reduction is prevented, and the blood fat is regulated, so that the gliquidone compound preparation is more applicable to patients suffering from diabetic nephropathy.

The invention relates to a traditional Chinese medicine composite as well as a product and an application of the traditional Chinese medicine composite. The composite comprises the following traditional Chinese medicine raw materials in parts by weight: 20-40 parts of Astragalus mongholicus and 10-20 parts of mulberry and also comprises one or several of the following traditional Chinese medicine raw materials in parts by weight: 5-15 parts of salviae miltiorrhizae, 5-15 parts of angelica sinensis, 10-20 parts of processed fleece-flower root, 5-15 parts of rhizoma chuanxiong and 1-5 parts of pseudo-ginseng. The traditional Chinese medicine composite has better actions on lowering sugar, lowering fat, improving a blood rheology index, reducing urine protein or improving the creatinine clearance rate and especially has the actions on protecting the vascular endothelial cell, alleviating the damage degree of the endarterium and the like, and therefore the traditional Chinese medicine composite can be prepared into oral administration or external application products used for treating or controlling renal damage, neuropathy around limbs, high blood fat, impotence, prostatic hyperplasia, diabetes mellitus and complications, such as diabetic foot, diabetic nephropathy and diabetic retinal inflammation, and has good protecting action on the liver, the kidney, the pancreas and the intestinal mucosa.

The invention relates to a medicament for relieving alcoholism, prepared by the steps of: decocting kudzu root, loquat leaf, river snail, clam, fructus psoraleae, mung bean and liquorice in water to obtain decoction, concentrating the decoction, adding conventional auxiliary materials, adding purified water until the crude drug content is 1g/mL, filling and sterilizing to obtain the oral liquid preparation. The medicament provided by the invention has the efficacies of resolving heat, reducing pathogenic fire, expelling toxin, harmonizing the stomach, lowering the adverse flow of qi, removing dampness and detoxifying, has an obvious effect on relieving alcoholism, has no subsidiary reactions such as hepatic and renal damage and the like caused by western medicines, has no drug resistance of antibiotics and the like, and has an effective rate of 100% proven by clinical observation.

The present invention relates to the use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker. More particularly, the present invention relates to a method for predicting or stratifying the risk of worsening renal function (WRF) in a patient at risk of renal injury or affected by renal injury. Levels of 1,25-dihydroxyvitamin D (1,25(OH)₂D) are measured in a biological sample and taken together with parathyroid hormone (PTH) levels to provide a ratio indicative of the risk of worsening renal function.

The invention belongs to the field of medicine, in particular to a new application of human urinary kallidinogenase and a pharmaceutical composition with the human urinary kallidinogenase. According to the new application of the human urinary kallidinogenase, the human urinary kallidinogenase is used for preparing medicine for treating hypertensive nephropathy, and the test discovers that the human urinary kallidinogenase is capable of lowering the arterial pressure of a rat with hypertensive nephropathy and improving the glomerular filtration rate and renal plasma flow of the rat with hypertensive nephropathy through regulating the micro-circulation of glomerulus, and has a certain treatment effect for renal damage. The pharmaceutical composition for treating the hypertensive nephropathy comprises the human urinary kallidinogenase and betahistine hydrochloride and further comprises pentoxifylline, the pharmaceutical composition has an obvious blood pressure reducing efficiency and has an obvious treatment effect for the damaged kidney, and the pharmaceutical composition for treating the hypertensive nephropathy is definite in effect, low in side effect and better for the recovery of a patient with hypertensive nephropathy.

The invention discloses a renal failure early-warning method and system based on urine specific gravity and urine volume monitoring. The method includes the steps: acquiring the urine specific gravity and stepping urine monitoring indexes of different patients, and building a database; performing training on a probabilistic neural network; calculating the urine specific gravity and the stepping urine monitoring indexes of the treated patients by the aid of the trained probabilistic neural network to obtain early-warning results. According to the method and the system, the detected urine specific gravity and the detected stepping urine monitoring indexes are analyzed, the probability of renal damage can be forecasted, renal lesions is timely discovered at the early stage of renal asymptomatic damage, and effective help is provided for clinic and early treatment.

The invention belongs to the technical field of good processing, and particularly relates to a health care tea with hair generating and kidney benefiting efficacies. The health care tea is prepared from the following raw materials in parts by weight: 20 to 30 parts of radix polygoni multiflori, 8 to 10 parts of prepared rehmannia roots, 10 to 15 parts of arborvitae tops, 10 to 15 parts of rhizoma polygonati, 5 to 8 parts of Chinese wolfberry fruits, 5 to 10 parts of radix angelicae sinensis, 5 to 8 parts of red dates, 8 to 10 parts of spatholobus stems, 5 to 10 parts of glossy privet fruits and 10 to 15 parts of mulberry fruits. The health care tea has the advantages that the natural traditional Chinese medicine raw materials are used; the preparation is simple and convenient; the medicine sources are wide; the cost is low; the effects of warming the kidney to strengthen yang, promoting blood circulation to remove blood stasis and clearing away heat and toxic materials are achieved; the kidney blood flow is improved; the urine protein is reduced; the renal damage is delayed; the recurrence rate is low; the complete reliving rate is high; the medicine property is mild; the absorption of scalp external nutrition can be effectively promoted; the blood circulation is promoted; the hair nutrition state is improved; the hair development speed is high; the effects of nourishing the spleen and the kidneys, nourishing the blood for tranquilization, promoting hair growth, blackening the hair, promoting blood circulation and eliminating toxin are achieved; the materials are made into a beverage; the use is convenient.

The invention provides a medicine for treating alcoholic renal injury. The medicine comprises the following raw material medicines of bigflower cape jasmine fruits, salvia prionitis, arundina chinensis, myrrh, taxillus chinensis, Chinese yam, glossy privet fruits, morinda officinalis, asiatic cornelian cherry fruits, saffron, fingered citron, szechwan chinaberry fruits, fungus umbellatus, phellodendron, fructus akebiae, fenugreek seeds, fructus aurantii, Chinese hawthorn leaves, reed rhizomes, radix gentianae macrophyllae and licorice roots. The medicine has a favorable intervention effect on the alcoholic renal damage through multiple target points, and shows favorable performance for resisting the alcoholic renal injury.